Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical piroxicam for prevention of capecitabine-related hand-foot syndrome
IRCT20241117063744N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in Erythrodysesthesia syndrome (PPE) comparing Topical piroxicam with Placebo (2 arms). Primary endpoint: Incidence and severity of hand-foot syndrome. Started Jan 2025; status: completed.
02
Drugs
piroxicam
03
Conditions
Erythrodysesthesia syndrome (PPE)
Beyond the preview
Go deeper on IRCT20241117063744N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241117063744N1.